Metabolic neuroimaging of myalgic encephalomyelitis/chronic fatigue syndrome and Long-COVID-Immunometabolism-CSCIED科技核心评价数据库-手机版

Metabolic neuroimaging of myalgic encephalomyelitis/chronic fatigue syndrome and Long-COVID

Metabolic neuroimaging of myalgic encephalomyelitis/chronic fatigue syndrome and Long-COVID

ES评分 0 浏览量：206 下载量：0

DOI	10.1097/IN9.0000000000000068
刊名	Immunometabolism IJ
年，卷(期)	2025, 7(4)
作者	Zhu, Yijuan; Quan, Patrick; Yamazaki, Tadahiro; Norweg, Anna; Natelson, Benjamin; Xu, Xiang,
作者单位	Icahn Sch Med Mt Sinai, Biomed Engn Imaging Inst, New York, NY 10029 USA;
摘要	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID are complex, disabling conditions that have emerged as significant public health challenges, affecting millions worldwide. Despite their growing prevalence, effective diagnostics and treatments remain limited, largely due to an incomplete understanding of their underlying pathophysiology. Both conditions share hallmark symptoms of chronic fatigue, cognitive dysfunction, and postexertional malaise, but their biological underpinnings remain to be elucidated. Neuroimaging offers a promising, noninvasive window into the brain's metabolic landscape and has the potential to uncover objective biomarkers for these conditions. In this mini review, we highlight recent advancements in metabolic neuroimaging, particularly positron emission tomography and magnetic resonance imaging/magnetic resonance spectroscopy, that reveal alterations in glucose and oxygen metabolism, neurotransmitter balance, and oxidative stress. These insights point toward shared disruptions in brain energy metabolism and neuroinflammatory processes, which may underlie the persistent symptoms in both ME/CFS and Long-COVID. Importantly, while some findings overlap, inconsistencies in metabolite profiles between ME/CFS and Long-COVID underscore the need for further stratification and longitudinal research. Standardizing definitions, such as identifying Long-COVID patients who meet ME/CFS diagnostic criteria, could help improve study comparability. By summarizing current imaging evidence, this review underscores the potential of neuroimaging to identify imaging biomarkers to advance the clinical diagnosis of Long-COVID and identify therapeutic targets for treatment development. As we continue to face the growing burden of Long-COVID and ME/CFS, metabolic imaging may serve as a powerful tool to bridge gaps in knowledge and accelerate progress toward effective care.
Abstract	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID are complex, disabling conditions that have emerged as significant public health challenges, affecting millions worldwide. Despite their growing prevalence, effective diagnostics and treatments remain limited, largely due to an incomplete understanding of their underlying pathophysiology. Both conditions share hallmark symptoms of chronic fatigue, cognitive dysfunction, and postexertional malaise, but their biological underpinnings remain to be elucidated. Neuroimaging offers a promising, noninvasive window into the brain's metabolic landscape and has the potential to uncover objective biomarkers for these conditions. In this mini review, we highlight recent advancements in metabolic neuroimaging, particularly positron emission tomography and magnetic resonance imaging/magnetic resonance spectroscopy, that reveal alterations in glucose and oxygen metabolism, neurotransmitter balance, and oxidative stress. These insights point toward shared disruptions in brain energy metabolism and neuroinflammatory processes, which may underlie the persistent symptoms in both ME/CFS and Long-COVID. Importantly, while some findings overlap, inconsistencies in metabolite profiles between ME/CFS and Long-COVID underscore the need for further stratification and longitudinal research. Standardizing definitions, such as identifying Long-COVID patients who meet ME/CFS diagnostic criteria, could help improve study comparability. By summarizing current imaging evidence, this review underscores the potential of neuroimaging to identify imaging biomarkers to advance the clinical diagnosis of Long-COVID and identify therapeutic targets for treatment development. As we continue to face the growing burden of Long-COVID and ME/CFS, metabolic imaging may serve as a powerful tool to bridge gaps in knowledge and accelerate progress toward effective care.
关键词	neuroimaging; metabolites; metabolic imaging; magnetic resonance spectroscopy; positron emission tomography; ME/CFS; Long-COVID
KeyWord	neuroimaging; metabolites; metabolic imaging; magnetic resonance spectroscopy; positron emission tomography; ME/CFS; Long-COVID
基金项目
页码	-

参考文献
相关文献

[1]. Natelson BH, Brunjes DL, Mancini D. Chronic fatigue syndrome and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2021;78(10):1056-67.

[2]. Bateman L, Bested AC, Bonilla HF, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: essentials of diagnosis and management. Mayo Clin Proc. 2021;96(11):2861-78.

[3]. Lim EJ, Ahn YC, Jang ES, et al. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med. 2020;18(1):100.

[4]. Nacul L, O’Boyle S, Palla L, et al. How myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) progresses: the natural history of ME/CFS. Front Neurol. 2020;11:826.

[5]. Schreiner P, Harrer T, Scheibenbogen C, et al. Human herpesvirus-6 reactivation, mitochondrial fragmentation, and the coordination of antiviral and metabolic phenotypes in myalgic encephalomyelitis/chronic fatigue syndrome. ImmunoHorizons. 2020;4(4):201-15.

[6]. Behan PO, Behan WM. Postviral fatigue syndrome. Crit Rev Neurobiol. 1988;4(2):157-78.

[7]. Hickie I, Davenport T, Wakefield D, et al.; Dubbo Infection Outcomes Study Group. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575.

[8]. Rasa S, Nora-Krukle Z, Henning N, et al.; European Network on ME/CFS (EUROMENE). Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med. 2018;16(1):268.

[9]. Tansey CM, Louie M, Loeb M, et al. One-Year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med. 2007;167(12):1312-20.

[10]. Lam MH, Wing YK, Yu MW, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med. 2009;169(22):2142-7.

[11]. Mancini DM, Brunjes DL, Lala A, et al. Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-coronavirus disease. JACC Heart Fail. 2021;9(12):927-37.

[12]. Norweg A, Yao L, Barbuto S, et al. Exercise intolerance associated with impaired oxygen extraction in patients with long COVID. Respir Physiol Neurobiol. 2023;313:104062.

[13]. Greenhalgh T, Sivan M, Perlowski A, et al. Long COVID: a clinical update. Lancet. 2024;404(10453):707-24.

[14]. Peluso MJ, Deeks SG. Mechanisms of long COVID and the path toward therapeutics. Cell. 2024;187(20):5500-29.

[15]. Altmann DM, Whettlock EM, Liu S, et al. The immunology of long COVID. Nat Rev Immunol. 2023;23(10):618-34.

[16]. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2023;401(10393):e21-33.

[17]. Soriano JB, Murthy S, Marshall JC, et al.; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-7.

[18]. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121(12):953-9.

[19]. Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas). 2021;57(5):418.

[20]. González-Hermosillo JA, Martínez-López JP, Carrillo-Lampón SA, et al. Post-acute COVID-19 symptoms, a potential link with myalgic encephalomyelitis/chronic fatigue syndrome: a 6-month survey in a Mexican Cohort. Brain Sci. 2021;11(6):760.

[21]. Twomey R, DeMars J, Franklin K, et al. Chronic fatigue and postexertional malaise in people living with long COVID: an observational study. Phys Ther. 2022;102(4):1-12.

[22]. Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-46.

[23]. Vernon SD, Zheng T, Do H, et al.; NIH Researching COVID to Enhance Recovery (RECOVER) Consortium. Incidence and prevalence of post-COVID-19 myalgic encephalomyelitis: a report from the observational RECOVER-adult study. J Gen Intern Med. 2025;40(5):1085-94.

[24]. López-Hernández Y, Monárrez-Espino J, López DAG, et al. The plasma metabolome of long COVID patients two years after infection. Sci Rep. 2023;13(1):12420.

[25]. Arron HE, Marsh BD, Kell DB, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: the biology of a neglected disease. Front Immunol. 2024;15:1386607.

[26]. Hornig M, Montoya JG, Klimas NG, et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv. 2015;1(1):e1400121.

[27]. Rekeland IG, Sørland K, Bruland O, et al. Activity monitoring and patient-reported outcome measures in myalgic encephalomyelitis/chronic fatigue syndrome patients. PLoS One. 2022;17(9):e0274472.

[28]. Alme TN, Andreasson A, Asprusten TT, et al.; Oslo Chronic Fatigue Consortium. Chronic fatigue syndromes: real illnesses that people can recover from. Scand J Prim Health Care. 2023;41(4):372-6.

[29]. Natarajan A, Shetty A, Delanerolle G, et al. A systematic review and meta-analysis of long COVID symptoms. Syst Rev. 2023;12(1):88.

[30]. Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54(1):1473-87.

[31]. Premraj L, Kannapadi NV, Briggs J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci. 2022;434:120162.

[32]. Kubota T, Kuroda N, Sone D. Neuropsychiatric aspects of long COVID: A comprehensive review. Psychiatry Clin Neurosci. 2023;77(2):84-93.

[33]. Jason LA, Islam M, Conroy K, et al. COVID-19 symptoms over time: comparing long-haulers to ME/CFS. Fatigue. 2021;9(2):59-68.

[34]. Weigel B, Eaton-Fitch N, Thapaliya K, et al. Illness presentation and quality of life in myalgic encephalomyelitis/chronic fatigue syndrome and post COVID-19 condition: a pilot Australian cross-sectional study. Qual Life Res. 2024;33(9):2489-507.

[35]. Komaroff AL, Lipkin WI. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol Med. 2021;27(9):895-906.

[36]. Grabowska AD, Westermeier F, Nacul L, et al. The importance of estimating prevalence of ME/CFS in future epidemiological studies of long COVID. Front Public Health. 2023;11:1275827.

[37]. Annesley SJ, Missailidis D, Heng B, et al. Unravelling shared mechanisms: insights from recent ME/CFS research to illuminate long COVID pathologies. Trends Mol Med. 2024;30(5):443-58.

[38]. Tommasin S, Giannì C, De Giglio L, et al. Neuroimaging techniques to assess inflammation in multiple sclerosis. Neuroscience. 2019;403:4-16.

[39]. Lai V, Mak HK, Yung AW, et al. Neuroimaging techniques in epilepsy. Hong Kong Med J. 2010;16(4):292-8.

[40]. Wang X, Huang W, Su L, et al. Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease. Mol Neurodegener. 2020;15(1):55.

[41]. Iorio-Morin C, Sarica C, Elias GJB, et al. Neuroimaging of psychiatric disorders. Prog Brain Res. 2022;270(1):149-69.

[42]. Marsland AL, Gianaros PJ, Kuan DC, et al. Brain morphology links systemic inflammation to cognitive function in midlife adults. Brain Behav Immun. 2015;48:195-204.

[43]. Sankowski R, Mader S, Valdés-Ferrer SI. Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci. 2015;9:28.

[44]. Sonneville R, Verdonk F, Rauturier C, et al. Understanding brain dysfunction in sepsis. Ann Intensive Care. 2013;3(1):15.

[45]. Finkelmeyer A, He J, Maclachlan L, et al. Grey and white matter differences in chronic fatigue syndrome—a voxel-based morphometry study. Neuroimage Clin. 2018;17:24-30.

[46]. Zeineh MM, Kang J, Atlas SW, et al. Right arcuate fasciculus abnormality in chronic fatigue syndrome. Radiology. 2015;274(2):517-26.

[47]. Barnden LR, Crouch B, Kwiatek R, et al. A brain MRI study of chronic fatigue syndrome: evidence of brainstem dysfunction and altered homeostasis. NMR Biomed. 2011;24(10):1302-12.

[48]. Shan ZY, Kwiatek R, Burnet R, et al. Progressive brain changes in patients with chronic fatigue syndrome: a longitudinal MRI study. J Magn Reson Imaging. 2016;44(5):1301-11.

[49]. de Lange FP, Kalkman JS, Bleijenberg G, et al. Gray matter volume reduction in the chronic fatigue syndrome. Neuroimage. 2005;26(3):777-81.

[50]. Vasilev Y, Blokhin I, Khoruzhaya A, et al. Routine brain MRI findings on the long-term effects of COVID-19: a scoping review. Diagnostics (Basel). 2023;13(15):2533.

[51]. Boito D, Eklund A, Tisell A, et al. MRI with generalized diffusion encoding reveals damaged white matter in patients previously hospitalized for COVID-19 and with persisting symptoms at follow-up. Brain Commun. 2023;5(6):fcad284.

[52]. Rua C, Raman B, Rodgers CT, et al. Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations. Brain. 2024;147(12):4121-30.

[53]. Raijmakers R, Roerink M, Keijmel S, et al. No signs of neuroinflammation in women with chronic fatigue syndrome or Q fever fatigue syndrome using the TSPO ligand
[(11)C]-PK11195. Neurol Neuroimmunol Neuroinflamm. 2022;9(1):e1113.

[54]. Nakatomi Y, Mizuno K, Ishii A, et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: An ¹¹C-(R)-PK11195 PET study. J Nucl Med. 2014;55(6):945-50.

[55]. Mergenthaler P, Lindauer U, Dienel GA, et al. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 2013;36(10):587-97.

[56]. Amiel SA. The consequences of hypoglycaemia. Diabetologia. 2021;64(5):963-70.

[57]. Minoshima S, Cross D, Thientunyakit T, et al. (18)F-FDG PET imaging in neurodegenerative dementing disorders: insights into subtype classification, emerging disease categories, and mixed dementia with copathologies. J Nucl Med. 2022;63(Suppl 1):2S-12S.

[58]. Tirelli U, Chierichetti F, Tavio M, et al. Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. Am J Med. 1998;105(3A):54S-8S.

[59]. Siessmeier T, Nix WA, Hardt J, et al. Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 2003;74(7):922-8.

[60]. Sahbai S, Kauv P, Abrivard M, et al. Severe posterior hypometabolism but normal perfusion in a patient with chronic fatigue syndrome/myalgic encephalomyelitis revealed by PET/MRI. Eur J Nucl Med Mol Imaging. 2019;46(2):531-2.

[61]. Verger A, Kas A, Dudouet P, et al. Visual interpretation of brain hypometabolism related to neurological long COVID: a French multicentric experience. Eur J Nucl Med Mol Imaging. 2022;49(9):3197-202.

[62]. Guedj E, Campion JY, Dudouet P, et al. (18)F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48(9):2823-33.

[63]. Horowitz T, Dudouet P, Campion JY, et al. Persistent brain metabolic impairment in long COVID patients with persistent clinical symptoms: a nine-month follow-up
[(18)F]FDG-PET study. Eur J Nucl Med Mol Imaging. 2024;51(11):3215-22.

[64]. Sakamoto JS, Lopes-Santos LE, Lacerda K, et al. Changes in cerebral glucose metabolism among mild long COVID patients: an
[18F]FDG PET/CT study. Braz J Med Biol Res. 2024;57:e14228.

[65]. Dressing A, Bormann T, Blazhenets G, et al. Neuropsychologic profiles and cerebral glucose metabolism in neurocognitive Long COVID syndrome. J Nucl Med. 2022;63(7):1058-63.

[66]. Frackowiak RS, Lenzi GL, Jones T, et al. Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man using 15O and positron emission tomography: theory, procedure, and normal values. J Comput Assist Tomogr. 1980;4(6):727-36.

[67]. Mintun MA, Raichle ME, Martin WR, et al. Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. J Nucl Med. 1984;25(2):177-87.

[68]. Coles JP, Fryer TD, Smielewski P, et al. Incidence and mechanisms of cerebral ischemia in early clinical head injury. J Cereb Blood Flow Metab. 2004;24(2):202-11.

[69]. Ibaraki M, Miura S, Shimosegawa E, et al. Quantification of cerebral blood flow and oxygen metabolism with 3-dimensional PET and 15O: validation by comparison with 2-dimensional PET. J Nucl Med. 2008;49(1):50-9.

[70]. Ito H, Kubo H, Takahashi K, et al. Integrated PET/MRI scanner with oxygen-15 labeled gases for quantification of cerebral blood flow, cerebral blood volume, cerebral oxygen extraction fraction and cerebral metabolic rate of oxygen. Ann Nucl Med. 2021;35(4):421-8.

[71]. Xu X, Belani P, Jiang D, et al. Structural and Oxygen Metabolic Magnetic Resonance Imaging of long-COVID and ME/CFS. Paper presented at: The International Society of Magnetic Resonance in Medicine; May 4–9, 2024; Singapore.

[72]. Liu P, Ernst T, Liang H, et al. Elevated cerebral oxygen extraction in patients with post-COVID conditions. NeuroImmune Pharm Ther. 2024;3(3-4):169-74.

[73]. Shungu DC, Weiduschat N, Murrough JW, et al. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed. 2012;25(9):1073-87.

[74]. Mathew SJ, Mao X, Keegan KA, et al. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed. 2009;22(3):251-8.

[75]. Natelson BH, Vu D, Coplan JD, et al. Elevations of ventricular lactate levels occur in both chronic fatigue syndrome and fibromyalgia. Fatigue. 2017;5(1):15-20.

[76]. Natelson BH, Mao X, Stegner AJ, et al. Multimodal and simultaneous assessments of brain and spinal fluid abnormalities in chronic fatigue syndrome and the effects of psychiatric comorbidity. J Neurol Sci. 2017;375:411-6.

[77]. Mueller C, Lin JC, Sheriff S, et al. Evidence of widespread metabolite abnormalities in Myalgic encephalomyelitis/chronic fatigue syndrome: assessment with whole-brain magnetic resonance spectroscopy. Brain Imaging Behav. 2020;14(2):562-72.

[78]. Vion-Dury J, Meyerhoff DJ, Cozzone PJ, et al. What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? J Neurol. 1994;241(6):354-71.

[79]. Kanagasabai K, Palaniyappan L, Théberge J. Precision of metabolite-selective MRS measurements of glutamate, GABA and glutathione: a review of human brain studies. NMR Biomed. 2024;37(3):e5071.

[80]. Thapaliya K, Marshall-Gradisnik S, Eaton-Fitch N, et al. Imbalanced brain neurochemicals in long COVID and ME/CFS: a preliminary study using MRI. Am J Med. 2025;138(3):567-74.e1.

[81]. Wilson M, Andronesi O, Barker PB, et al. Methodological consensus on clinical proton MRS of the brain: review and recommendations. Magn Reson Med. 2019;82(2):527-50.

[82]. Near J, Harris AD, Juchem C, et al. Preprocessing, analysis and quantification in single-voxel magnetic resonance spectroscopy: experts’ consensus recommendations. NMR Biomed. 2021;34(5):e4257.

[83]. Brooks JC, Roberts N, Whitehouse G, et al. Proton magnetic resonance spectroscopy and morphometry of the hippocampus in chronic fatigue syndrome. Br J Radiol. 2000;73(875):1206-8.

[84]. Lin A, Andronesi O, Bogner W, et al.; Experts' Working Group on Reporting Standards for MR Spectroscopy. Minimum reporting standards for in vivo magnetic resonance spectroscopy (MRSinMRS): experts’ consensus recommendations. NMR Biomed. 2021;34(5):e4484.

[85]. Marinkovic K, White DR, Alderson Myers A, et al. Cortical GABA levels are reduced in post-acute COVID-19 syndrome. Brain Sci. 2023;13(12):1666.

[86]. Moffett JR, Arun P, Ariyannur PS, et al. N-Acetylaspartate reductions in brain injury: impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation. Front Neuroenergetics. 2013;5:11.

[87]. Joyce JM, La PL, Walker R, et al. Magnetic resonance spectroscopy of traumatic brain injury and subconcussive hits: a systematic review and meta-analysis. J Neurotrauma. 2022;39(21-22):1455-76.

[88]. Chang L, Munsaka SM, Kraft-Terry S, et al. Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain. J Neuroimmune Pharmacol. 2013;8(3):576-93.

[89]. Paslakis G, Traber F, Roberz J, et al. N-acetyl-aspartate (NAA) as a correlate of pharmacological treatment in psychiatric disorders: a systematic review. Eur Neuropsychopharmacol. 2014;24(10):1659-75.

[90]. Chiu PW, Mak HK, Yau KK, et al. Metabolic changes in the anterior and posterior cingulate cortices of the normal aging brain: proton magnetic resonance spectroscopy study at 3 T. Age (Dordr). 2014;36(1):251-64.

[91]. Weinberg BD, Kuruva M, Shim H, et al. Clinical applications of magnetic resonance spectroscopy in brain tumors: from diagnosis to treatment. Radiol Clin North Am. 2021;59(3):349-62.

[92]. Puri BK, Counsell SJ, Zaman R, et al. Relative increase in choline in the occipital cortex in chronic fatigue syndrome. Acta Psychiatr Scand. 2002;106(3):224-6.

[93]. Tomoda A, Miike T, Yamada E, et al. Chronic fatigue syndrome in childhood. Brain Dev. 2000;22(1):60-4.

[94]. Chaudhuri A, Condon BR, Gow JW, et al. Proton magnetic resonance spectroscopy of basal ganglia in chronic fatigue syndrome. Neuroreport. 2003;14(2):225-8.

[95]. Lana JV, Rios A, Takeyama R, et al. Nebulized glutathione as a key antioxidant for the treatment of oxidative stress in neurodegenerative conditions. Nutrients. 2024;16(15):2476.

[96]. Lv H, Zhen C, Liu J, et al. Unraveling the potential role of glutathione in multiple forms of cell death in cancer therapy. Oxid Med Cell Longev. 2019;2019:3150145.

[97]. Godlewska BR, Williams S, Emir UE, et al. Neurochemical abnormalities in chronic fatigue syndrome: a pilot magnetic resonance spectroscopy study at 7 Tesla. Psychopharmacology (Berl). 2022;239(1):163-71.

[98]. Paul BD, Lemle MD, Komaroff AL, et al. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc Natl Acad Sci U S A. 2021;118(34):e2024358118.

[99]. Yegiazaryan A, Abnousian A, Alexander LJ, et al. Recent developments in the understanding of immunity, pathogenesis and management of COVID-19. Int J Mol Sci . 2022;23(16):9297.

[100]. Poletti S, Paolini M, Mazza MG, et al.; Covid BioB Outpatients Clinic Study Group. Lower levels of glutathione in the anterior cingulate cortex associate with depressive symptoms and white matter hyperintensities in COVID-19 survivors. Eur Neuropsychopharmacol. 2022;61:71-7.

[101]. Mairal E, Barberon B, Laine N, et al. Reversible widespread brain (18)F-FDG PET hypometabolism in chronic fatigue syndrome treated by hyperbaric oxygen therapy. Eur J Nucl Med Mol Imaging. 2021;48(5):1680-1.

[102]. Weiduschat N, Mao X, Vu D, et al. N-Acetylcysteine Supplementation Elevates Human Brain Glutathione In Vivo: A Proof-of-Concept Study using J-edited 1H MRS. Paper presented at: International Society of Magnetic Resonance in Medicine; June 22-27, 2017; Honolulu, HI, USA.

引用本文

Zhu, Yijuan; Quan, Patrick; Yamazaki, Tadahiro; Norweg, Anna; Natelson, Benjamin; Xu, Xiang. Metabolic neuroimaging of myalgic encephalomyelitis/chronic fatigue syndrome and Long-COVID [J]. Immunometabolism. 2025; 7; (4). - .

文献评论

相关学者

相关机构